CIMAvax-EGF: Therapeutic vaccine for lung cancer based on antigen-antibody mechanisms

Abstract

Introduction: Among the vaccines created to combat cancer, Cimavax-EGF is the first therapeutic vaccine against non-small cell lung cancer in advanced stages IIIB or IV. The vaccine contains the recombinant human epidermal growth factor.
Objective: To describe the antigen-antibody mechanism of the therapeutic CIMAVAX-EGF vaccine in the treatment of small cell lung cancer.
Method: A bibliographic review, using lung cancer; Cimavax-EGF; Immunological mechanism, was carried out; it included articles from SciELO, PubMed, Google Scholar and EBSCO, as well as Cuban medical journals. A search of 25 bibliographic references was done, where a sample of 17 bibliographies was chosen.
Development: CIMAVAX-EGF Action Mechanism consists of the stimulation of the patient's immune system, inducing the formation of specific antibodies against his own EGF as the starting point of immunization, breaking immune tolerance against his own protein.
Conclusions: The main clinical benefit of the vaccine has been shown with an increase in the improvement of life quality, as well as extensive safety profile, given by the immunological mechanisms that govern its effect on the body.